PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open label study aimed at assessing the pharmacokinetics,
pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in
children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy
(CTX)